F-Star: Louis Kayitalire
In another move that sees an individual exit BMS to take a leadership position at another company, F-Star has brought in Louis Kayitalire as CMO.
The position has been newly-created for Kayitalire, which the biotech suggested is part of its transition to a ‘wholly-owned portfolio’ organisation that would also see it expand its clinical operation capabilities and accelerate its pipeline.
The company’s lead product candidate is FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody currently in a Phase I clinical trial.
At BMS, Kayitalire had performed the role of VP of immune-oncology for over three years, which was part of the reasoning behind bringing him in to work on F-Star’s oncology pipeline, the biotech’s CEO suggested.
Eliot Forster, CEO of F-star, said, “[Kayitalire]’s oncology expertise and extensive experience advancing clinical research programmes will be invaluable at this stage in F-star’s evolution as we accelerate development of our lead product candidate, FS118, and work to rapidly progress more assets into the clinic.”
